Podcast: Enhertu for HER2-Low Breast Cancer

Options
Moderators
Moderators Member Posts: 25,912

Enhertu for HER2-Low Breast Cancer
Jul 8, 2022

Brian Wojciechowski, MD, explains what HER2-low breast is and the exciting results showing that Enhertu can help treat it.

At the recent 2022 American Society of Clinical Oncology Annual Meeting, researchers presented results showing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki), which is a type of medicine doctors call an antibody-drug conjugate, improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.

Listen to the podcast to hear Dr. Wojciechowski explain:

  • what HER2-low breast cancer is
  • how Enhertu works
  • how the results of the DESTINY-Breast-04 study will change practice
Listen now or read the transcript.

Comments

Categories